LONDON – Adding to the immediate and obvious toll of serious illness and death, COVID-19 seems likely to be fueling development of resistance to antibiotic drugs, according to the findings of the most comprehensive analysis to date.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amryt, BMS, Boehringer, Inmune, Janssen, Kamada, Karyopharm, Kedrion, Novartis, RDIF, Roche, Scynexis, Sinovac, Soleno, Stealth, Tetra, Zealand.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: AC, Aptamer, Astrazeneca, Bolt, Centivax, Fusion, Genmab, Genscript, Harvard, Havn, Humanetics, Kahr Medical, Lianbio, Ligand, Lyra, Moderna, Nurix, Obatala, Odyssey, Pinotbio, Porton, Proteros, Progenity, Repertoire, Samsung, Selecta, Sesen, Sorrento, Surrozen, Therapeutic Solutions, Thermo, Vaxxas.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, AC, Arthrosi, Astrazeneca, Briacell, Bridge, Calcimedica, Celltrion, Eli Lilly, Gensight, Hightide, Intensity, Janssen, Kezar, Lixte, Logicbio, Mereo, Metacrine, Pharmazz, Transcenta, Travere, Virios.

Alr Technologies, Altaris, Apyx Medical, Avails Medical, Brainsway, Distal Solutions, Distimp, Echosens, Excalibur Healthcare Services, Genetic Technologies, Global Healthcare SG, Gyrus Capital, Illumina, Infinity Biologics, Jiangsu Vedkang Medical Science and Technology, Kailo Medical, Livanova, Medo, Microbix Biosystems, Myriad Genetics, Next Generation Genomic, Paragon 28, Pentax Medical, Renovacare, Resonetics, Sdt Molecular, Solesis, Spineway, Zoll Medical.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akebia, Alkermes, Beyondspring, Biontech, BMS, Bridgebio, CTI, Ipsen, J&J, Lannett, Mycovia, Moderna, Neuren, Neurorx, Otsuka, Paratek, Pfizer, RDIF, Respirent, Seres, Spectrum, Stallergenes.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Advanz, Anheart, Biological, , Citrine, Defence, Diurnal, Glaxosmithkline, Hopstem, Immutep, Innovent, Lindis, Merck, Neurophth, Nexturn, NMD, Novabiotics, Polyphor, Providence, Rosvivo, Sanofi, Sutro, Vaxil.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: AB, Alnylam, Annovis, Basilea, Biogen, Bio-Thera, Curevac, Dilafor, Janssen, Jasper, Liminal, Lineage, Menarini, Neuren, NH Theraguix, Nicox, Noxxon, Rhovac, Sanofi, Santhera, Tracon, Ultimovacs, Viracta.